Neoadjuvant systemic therapy is increasingly recommended for both TNBC and HER2+ breast cancer, with several advantages, including tumour downstaging, increased eligibility for breast conservation surgery, and the generation of in vivo sensitivity data regarding the given systemic therapy. The gene discussed is ERBB2; the disease is neoplasm.